Chong Kun Dang Holdings

Sky Labs is a technology company focused on developing innovative wearable devices for health monitoring, particularly a cuffless ring-type blood pressure monitor and a device known as the Cardio Tracker (CART). The CART is designed for continuous monitoring of atrial fibrillation, a common and often undiagnosed heart condition affecting many individuals over 40. This device can be worn comfortably on any finger and is both waterproof and dustproof, allowing users to wear it throughout their daily activities without interruption. It operates without user intervention, automatically detecting and recording atrial fibrillation, which users can track via a smartphone application. The device aims not only to assist individuals in managing their heart health but also to provide valuable data to healthcare professionals for accurate diagnosis. Sky Labs is currently conducting clinical trials in collaboration with Seoul National University Hospital to validate the performance of its technology, with an initial focus on the atrial fibrillation patient market in Finland, and an extended target market of millions worldwide. The company is also partnering with Bayer to explore further healthcare innovations.

# Nodit Nodit is a Web3 development platform specialized in blockchain data. Nodit aims to provide enterprise-grade multi-chain Web3 infrastructure accessible to everyone. By offering reliable node infrastructure with 99.9% uptime and consistent ready-to-query blockchain data at an affordable price, we are facilitating developers’ entry into the Web3 world. # Lambda256 Lambda256, the blockchain tech arm of Dunamu, developed and operates Nodit, which enhances efficiency in managing tasks like blockchain network setup, node operation, and data processing for Ethereum, Arbitrum, and Aptos and Luniverse, a cloud-based blockchain infrastructure platform. Lambda256 also offers a travel rule solution to meet FATF guidelines, improving security and compliance for virtual asset transactions. The company secured Series A funding, followed by Series B funding in December 2021, achieving a total accumulated investment of approximately +80 million USD.

BIORCHESTRA is a biotech company that develops RNA-based therapeutics for treating neuroinflammatory diseases. They focus on changing the therapeutic paradigm from treating the symptoms to providing a fundamental cure for diseases. BIORCHESTRA develops neuroinflammatory disease therapeutics, with a particular emphasis on comprehensive patient care. BIORCHESTRA's complementary discovery platforms range from diagnosis to treatment monitoring.

G+FLAS Life Sciences Co., Ltd. is a South Korean biotechnology company founded in 2014, specializing in advanced genome editing technologies, particularly CRISPR-Cas. The company focuses on developing innovative agricultural products, most notably vitamin D3-enriched tomatoes, which aim to enhance nutritional value and cater to the growing demand for functional foods. By applying its proprietary CRISPR-PLUS technology, G+FLAS is able to create glycoengineered plants with improved health benefits, addressing critical market needs in both agricultural biotechnology and human health. The company also operates plant cultivation facilities for pharmaceuticals and engages in research related to anticancer therapies and drug development. Its strategic partnership with Bayer facilitates the commercialization of its technologies, positioning G+FLAS for significant growth in the global market. The company's innovations not only offer a sustainable, plant-based source of vitamin D3 but also target health-conscious consumers, aiming to capture a substantial share of the US tomato market, valued at approximately $18 billion. With its cutting-edge solutions, G+FLAS Life Sciences is poised to make a significant impact on global health and agricultural sustainability.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.